About NKA BIO, INC
NKA Bio is a biotech startup developing new medicines to press pause on death and buy more time for life-saving care, based on research by the first Director of Emergency Medicine at Johns Hopkins. The company operates R&D facilities in Baltimore, Maryland, and is working on a lead drug candidate, NKA01, set to enter the clinic in 18 months.
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| ANTI-SHOCK TOXIN ANTIBODY DRUG FOR COMBAT CASUALTY CARE | Department of Defense | $73K | |
| ANTI-SHOCK INJECTION TO IMPROVE COMBAT CASUALTY CARE | Department of Defense | $1.2M |
Is this your company?
Claim NKA BIO, INC to unlock the federal & state contracts GovIntel's AI has matched to you right now — plus your own scored past-performance, who you're up against, and who's risky to team with.
Claim NKA BIO, INC & see your matchesFree to claim. Takes about a minute.
Data compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate, or want this page removed? Request a correction or removal.